Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT6AZXG)

• DTT Name: TNF alpha converting enzyme (ADAM17) DTT Info
• Gene Name: ADAM17

Molecule-Related Drug & Molecule List

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apratastat	DM8W4N9	Rheumatoid arthritis	FA20	Phase 2	[1]
Aderbasib	DMYOMSC	Breast cancer	2C60-2C65	Phase 1/2	[2]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GW-3333	DM3PMAZ	Chronic obstructive pulmonary disease	CA22	Preclinical	[3]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DPC-333	DM4JBQD	Inflammatory bowel disease	DD72	Terminated	[3]

13 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-(4-bromophenylsulfonamido)-N-hydroxyacetamide	DMY5STK	Discovery agent	N.A.	Investigative	[4]
2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide	DM3PWK7	Discovery agent	N.A.	Investigative	[4]
Batimistat	DMTQX1G	Discovery agent	N.A.	Investigative	[5]
CH4474	DMP9UHT	Discovery agent	N.A.	Investigative	[6]
IK-862	DMJA4UE	Discovery agent	N.A.	Investigative	[7]
IM-491	DMUQO86	Discovery agent	N.A.	Investigative	[8]
N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide	DM50NKS	Discovery agent	N.A.	Investigative	[4]
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	DMWXUCT	Discovery agent	N.A.	Investigative	[9]
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	DMA6EPH	Discovery agent	N.A.	Investigative	[9]
PKF-241-466	DM04C9V	Discovery agent	N.A.	Investigative	[10]
PKF-242-484	DMNDLAS	Discovery agent	N.A.	Investigative	[10]
SL422	DM3I2US	Discovery agent	N.A.	Investigative	[11]
SR-973	DMU48OD	Discovery agent	N.A.	Investigative	[12]

References

• [1] Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
• [2] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [3] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [4] Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35.
• [5] The secretases that cleave angiotensin converting enzyme and the amyloid precursor protein are distinct from tumour necrosis factor-alpha convertase. FEBS Lett. 1998 Jul 10;431(1):63-5.
• [6] Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. Clin Exp Immunol. 2004 Jan;135(1):146-53.
• [7] Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem. 2008 Oct 1;16(19):8781-94.
• [8] Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):241-6.
• [9] Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.
• [10] Current perspective of TACE inhibitors: a review. Bioorg Med Chem. 2009 Jan 15;17(2):444-59.
• [11] Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
• [12] Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.